Obiettivo Up to 15% of the EU and USA population suffer from Chronic Constipation. The most affected collectives are women, aging people and patients with Neurogenic Bowel disorders related to Spinal cord injury, Parkinson and Multiple Sclerosis. Constipation causes a painful evacuation, faecal impaction and faecal incontinence, which have a big negative impact on the quality of life of these patients.USMIMA S.L. created in 2014, offers MOWOOT, a non-pharmacological, non-invasive solution to relieve chronical constipation, without side-effects, in form of a wearable class II medical device that automatically emulates the abdominal massage techniques of professional therapists via a number of actuators. A pilot study with chronically constipated patients has already shown that the daily use of MOWOOT ameliorates idiopathic chronic constipation (TRL7). USMIMA wants to target a 90B M€ market of 150 million people with chronic constipation identified. A feasibility study showed that, in order to target this market and increase the influence on target clients, USMIMA has to priorize the following activities during this phase 2:• Conduct a larger clinical study as a marketing strategy to build confidence in the medical sector and promote MOWOOT prescriptions• Upgrade Mowoot 1.0 prototype to Mowoot 2.0 product, by adding cloud and smart services and other features required by users• Reduce costs (below current 500€) through scaling the manufacturing process MOWOOT is expected to produce a big impact on USMIMA by: • Generating 2.5 M€ of EBITDA by 2018• Incorporating 5 new specialized employees to complement current staff profiles • Introducing MOWOOT products in EU and USA markets by 2019Moreover, MOWOOT will empower patients and elderly people, enhance well-being among the society, increase autonomy and reduce the increasing health care expenses due to aging population and the derived long-term cares. Campo scientifico engineering and technologymechanical engineeringmanufacturing engineeringnatural sciencescomputer and information sciencesinternetinternet of thingsnatural sciencescomputer and information sciencessoftwaresoftware developmentmedical and health sciencesbasic medicineneurologymultiple sclerosismedical and health sciencesbasic medicineneurologyparkinson Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Argomento(i) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-2-2016-2017 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore USMIMA SL Contribution nette de l'UE € 1 142 504,13 Indirizzo AVDA. NURIA 22 URB. MAS DE CAN PI DE CERVELLO 08758 CERVELLO BARCELONA Spagna Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Este Cataluña Barcelona Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 632 148,75
